Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese

European Journal of Pharmaceutical Sciences

Volumn 29, Issue 1, 2006, Pages 14-21

  Guan, Su ^a   Huang, Min ^a   Chan, Eli ^b   Chen, Xiao ^a   Duan, Wei ^c   Zhou, Shu Feng ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Chinese; CYP2B6; Ethnicity; Single nucleotide polymorphism

Indexed keywords

CYTOCHROME P450 2B6;

ADULT; ARTICLE; ASIAN; CHINESE; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; MALE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; ARYL HYDROCARBON HYDROXYLASES; CHINA; DNA; EUROPEAN CONTINENTAL ANCESTRY GROUP; EXONS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INDICATORS AND REAGENTS; MALE; OXIDOREDUCTASES, N-DEMETHYLATING; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEX CHARACTERISTICS; TERMINOLOGY;

EID: 33747789083     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.04.004     Document Type: Article

References (56)

1. Ariyoshi N., Miyazaki M., Toide K., Sawamura Y., and Kamataki T. A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation. Biochem. Biophys. Res. Commun. 281 (2001) 1256-1260
2. Burger D., van der Heiden I., la Porte C., van der Ende M., Groeneveld P., Richter C., Koopmans P., Kroon F., Sprenger H., Lindemans J., Schenk P., and van Schaik R. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br. J. Clin. Pharmacol. 61 (2006) 148-154
3. Chang T.K., Bandiera S.M., and Chen J. Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels. Drug Metab. Dispos. 31 (2003) 7-10
4. Chang T.K., Weber G.F., Crespi C.L., and Waxman D.J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53 (1993) 5629-5637
5. Cho J.Y., Lim H.S., Chung J.Y., Yu K.S., Kim J.R., Shin S.G., and Jang I.J. Haplotype structure and allele frequencies of CYP2B6 in a Korean population. Drug Metab. Dispos. 32 (2004) 1341-1344
6. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162 (1987) 156-159
7. Chowbay B., Zhou S., and Lee E.J. An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab. Rev. 37 (2005) 327-378
8. Code E.L., Crespi C.L., Penman B.W., Gonzalez F.J., Chang T.K., and Waxman D.J. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab. Dispos. 25 (1997) 985-993
9. Crewe H.K., Notley L.M., Wunsch R.M., Lennard M.S., and Gillam E.M. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab. Dispos. 30 (2002) 869-874
10. Domanski T.L., Schultz K.M., Roussel F., Stevens J.C., and Halpert J.R. Structure-function analysis of human cytochrome P-450 2B6 using a novel substrate, site-directed mutagenesis, and molecular modeling. J. Pharmacol. Exp. Ther. 290 (1999) 1141-1147
11. Ekins S., Vandenbranden M., Ring B.J., Gillespie J.S., Yang T.J., Gelboin H.V., and Wrighton S.A. Further characterization of the expression in liver and catalytic activity of CYP2B6. J. Pharmacol. Exp. Ther. 286 (1998) 1253-1259
12. Ekins S., VandenBranden M., Ring B.J., and Wrighton S.A. Examination of purported probes of human CYP2B6. Pharmacogenetics 7 (1997) 165-179
13. Evans D.A., McLeod H.L., Pritchard S., Tariq M., and Mobarek A. Interethnic variability in human drug responses. Drug Metab. Dispos. 29 (2001) 606-610
14. Faucette S.R., Hawke R.L., Lecluyse E.L., Shord S.S., Yan B., Laethem R.M., and Lindley C.M. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab. Dispos. 28 (2000) 1222-1230
15. Gerber J.G., Rhodes R.J., and Gal J. Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16 (2004) 36-44
16. Gervot L., Rochat B., Gautier J.C., Bohnenstengel F., Kroemer H., de Berardinis V., Martin H., Beaune P., and de Waziers I. Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9 (1999) 295-306
17. Gonzalez F.J. The molecular biology of cytochrome P-450s. Pharmacol. Rev. 40 (1989) 243-288
18. Haas D.W., Ribaudo H.J., Kim R.B., Tierney C., Wilkinson G.R., Gulick R.M., Clifford D.B., Hulgan T., Marzolini C., and Acosta E.P. Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Aids 18 (2004) 2391-2400
19. Haas D.W., Smeaton L.M., Shafer R.W., Robbins G.K., Morse G.D., Labbe L., Wilkinson G.R., Clifford D.B., D'Aquila R.T., De Gruttola V., Pollard R.B., Merigan T.C., Hirsch M.S., George Jr. A.L., Donahue J.P., and Kim R.B. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J. Infect. Dis. 192 (2005) 1931-1942
20. Hesse L.M., He P., Krishnaswamy S., Hao Q., Hogan K., von Moltke L.L., Greenblatt D.J., and Court M.H. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 14 (2004) 225-238
21. Heyn H., White R.B., and Stevens J.C. Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin. Drug Metab. Dispos. 24 (1996) 948-954
22. Hiratsuka M., Takekuma Y., Endo N., Narahara K., Hamdy S.I., Kishikawa Y., Matsuura M., Agatsuma Y., Inoue T., and Mizugaki M. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur. J. Clin. Pharmacol. 58 (2002) 417-421
23. Hustert E., Zibat A., Presecan-Siedel E., Eiselt R., Mueller R., Fuss C., Brehm I., Brinkmann U., Eichelbaum M., Wojnowski L., and Burk O. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab. Dispos. 29 (2001) 1454-1459
24. Jaffe C.A., Ocampo-Lim B., Guo W., Krueger K., Sugahara I., DeMott-Friberg R., Bermann M., and Barkan A.L. Regulatory mechanisms of growth hormone secretion are sexually dimorphic. J. Clin. Invest. 102 (1998) 153-164
25. Jinno H., Tanaka-Kagawa T., Ohno A., Makino Y., Matsushima E., Hanioka N., and Ando M. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab. Dispos. 31 (2003) 398-403
26. Kent U.M., Mills D.E., Rajnarayanan R.V., Alworth W.L., and Hollenberg P.F. Effect of 17-alpha-ethynylestradiol on activities of cytochrome P450 2B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J. Pharmacol. Exp. Ther. 300 (2002) 549-558
27. Kim H., Wang R.S., Elovaara E., Raunio H., Pelkonen O., Aoyama T., Vainio H., and Nakajima T. Cytochrome P450 isozymes responsible for the metabolism of toluene and styrene in human liver microsomes. Xenobiotica 27 (1997) 657-665
28. Klein K., Lang T., Saussele T., Barbosa-Sicard E., Schunck W.H., Eichelbaum M., Schwab M., and Zanger U.M. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenet. Genomics 15 (2005) 861-873
29. Kobayashi Y., Fang X., Szklarz G.D., and Halpert J.R. Probing the active site of cytochrome P450 2B1: metabolism of 7-alkoxycoumarins by the wild type and five site-directed mutants. Biochemistry 37 (1998) 6679-6688
30. Koyama E., Chiba K., Tani M., and Ishizaki T. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J. Pharmacol. Exp. Ther. 281 (1997) 1199-1210
31. Lamba V., Lamba J., Yasuda K., Strom S., Davila J., Hancock M.L., Fackenthal J.D., Rogan P.K., Ring B., Wrighton S.A., and Schuetz E.G. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J. Pharmacol. Exp. Ther. 307 (2003) 906-922
32. Lang T., Klein K., Fischer J., Nussler A.K., Neuhaus P., Hofmann U., Eichelbaum M., Schwab M., and Zanger U.M. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11 (2001) 399-415
33. Lang T., Klein K., Richter T., Zibat A., Kerb R., Eichelbaum M., Schwab M., and Zanger U.M. Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J. Pharmacol. Exp. Ther. 311 (2004) 34-43
34. Lim Y.P., Liu C.H., Shyu L.J., and Huang J.D. Functional characterization of a novel polymorphism of pregnane X receptor, Q158K, in Chinese subjects. Pharmacogenet. Genomics 15 (2005) 337-341
35. Lindley C., Hamilton G., McCune J.S., Faucette S., Shord S.S., Hawke R.L., Wang H., Gilbert D., Jolley S., Yan B., and LeCluyse E.L. The effect of cyclophosphamide with and without dexamethasone on cytochrome P450 3A4 and 2B6 in human hepatocytes. Drug Metab. Dispos. 30 (2002) 814-822
36. Miksys S., Lerman C., Shields P.G., Mash D.C., and Tyndale R.F. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 45 (2003) 122-132
37. Nakajima T., Elovaara E., Gonzalez F.J., Gelboin H.V., Raunio H., Pelkonen O., Vainio H., and Aoyama T. Styrene metabolism by cDNA-expressed human hepatic and pulmonary cytochromes P450. Chem. Res. Toxicol. 7 (1994) 891-896
38. Newcombe R.G. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat. Med. 17 (1998) 857-872
39. Rae J.M., Soukhova N.V., Flockhart D.A., and Desta Z. Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab. Dispos. 30 (2002) 525-530
40. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab. Rev. 34 (2002) 83-448
41. Richter T., Murdter T.E., Heinkele G., Pleiss J., Tatzel S., Schwab M., Eichelbaum M., and Zanger U.M. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J. Pharmacol. Exp. Ther. 308 (2004) 189-197
42. Rodriguez-Novoa S., Barreiro P., Rendon A., Jimenez-Nacher I., Gonzalez-Lahoz J., and Soriano V. Influence of 516G > T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin. Infect. Dis. 40 (2005) 1358-1361
43. Rotger M., Colombo S., Furrer H., Bleiber G., Buclin T., Lee B.L., Keiser O., Biollaz J., Decosterd L., and Telenti A. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet. Genomics 15 (2005) 1-5
44. Santisteban I., Povey S., Shephard E.A., and Phillips I.R. The major phenobarbital-inducible cytochrome P-450 gene subfamily (P450IIB) mapped to the long arm of human chromosome 19. Ann. Hum. Genet. 52 Pt2 (1988) 129-135
45. Schmidt R., Baumann F., Hanschmann H., Geissler F., and Preiss R. Gender difference in ifosfamide metabolism by human liver microsomes. Eur. J. Drug Metab. Pharmacokinet. 26 (2001) 193-200
46. Scott E.E., Spatzenegger M., and Halpert J.R. A truncation of 2B subfamily cytochromes P450 yields increased expression levels, increased solubility, and decreased aggregation while retaining function. Arch. Biochem. Biophys. 395 (2001) 57-68
47. Spatzenegger M., Liu H., Wang Q., Debarber A., Koop D.R., and Halpert J.R. Analysis of differential substrate selectivities of CYP2B6 and CYP2E1 by site-directed mutagenesis and molecular modeling. J. Pharmacol. Exp. Ther. 304 (2003) 477-487
48. Svensson U.S., and Ashton M. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br. J. Clin. Pharmacol. 48 (1999) 528-535
49. Teglund S., McKay C., Schuetz E., van Deursen J.M., Stravopodis D., Wang D., Brown M., Bodner S., Grosveld G., and Ihle J.N. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 93 (1998) 841-850
50. Wang H., and Negishi M. Transcriptional regulation of cytochrome p450 2B genes by nuclear receptors. Curr. Drug. Metab. 4 (2003) 515-525
51. Ward B.A., Gorski J.C., Jones D.R., Hall S.D., Flockhart D.A., and Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 306 (2003) 287-300
52. Wei P., Zhang J., Egan-Hafley M., Liang S.G., and Moore D.D. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 407 (2000) 920-923
53. Wojcikowski J., Pichard-Garcia L., Maurel P., and Daniel W.A. Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br. J. Pharmacol. 138 (2003) 1465-1474
54. Xie H.G., Kim R.B., Wood A.J.J., and Stein C.M. Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 815-850
55. Yamano S., Nhamburo P.T., Aoyama T., Meyer U.A., Inaba T., Kalow W., Gelboin H.V., McBride O.W., and Gonzalez F.J. cDNA cloning and sequence and cDNA-directed expression of human P450 IIB1: identification of a normal and two variant cDNAs derived from the CYP2B locus on chromosome 19 and differential expression of the IIB mRNAs in human liver. Biochemistry 28 (1989) 7340-7348
56. Zukunft J., Lang T., Richter T., Hirsch-Ernst K.I., Nussler A.K., Klein K., Schwab M., Eichelbaum M., and Zanger U.M. A natural CYP2B6 TATA box polymorphism (-82T→ C) leading to enhanced transcription and relocation of the transcriptional start site. Mol. Pharmacol. 67 (2005) 1772-1782